Table 5 Grade 3+ acute toxicity and locoregional control: review of the literature for IMRT
Number of patients | Follow-up (months) | Locoregional control (%) | Treatment breaks (%) | Breaks (days) | Rates of grade 3+ GI toxicity (%) | Rates of grade 3+ skin toxicity (%) | Rate of grade 3 and 4 haematological toxicity (%) | Scale | |
|---|---|---|---|---|---|---|---|---|---|
Pepek et al.[13] | 47 | Median 14 | 90 (2-y) | 18 (AT) | Median 5 (2-7) | 10 | 0 | 24 | CTC V3 |
Bazan et al.[6] | 46 | Median | CTC V3 | ||||||
17 (3D) | 3D : 26 | 3D : 56.7 (3-y) | 3D : 88 (AT) | 3D : 12 | 3D : 29 | 3D : 41 | 3D : 29 | ||
29(IMRT | IMRT: 32 | IMRT : 91.9 (3-y) (P<0.01) | IMRT : 34.5 (90% AT, 10% NC) (P=0.001) | IMRT : 1.5 (P<0.0001) | IMRT: 7 | IMRT: 21 | IMRT : 21 | ||
Salama et al.[14] | 53 | Median | 83.9 (1.5-y) | 41.5 | Median | 15 | 38 | 59 | CTC V3 |
14.5 | (AT) | 4 (2-14) | |||||||
RTOG 0529 .[19] | 43 | 24 | 95 (2-y) | 40 | Median | 7 | 10 | 61 | CTC V3 |
(AT+NC) 35 (toxicity) | 2 (2-24) | ||||||||
Kachnic et al.[20] | 52 | 23.2 | 80 (2-y) | NR | NR | 22 | 20 | NR | CTC V3 |
Milano et al.[12] | 17 | 20.3 | 82 (2-y) | 24 (AT) | NR | 0 | 0 | 38 | RTOG |
Hodges et al.[17] | 6 | 25 | 100 (3-y) | 50 | 1- 3 | 67 | 0 | CTC V3 | |
Vautravers-Dewas et al. | 51 | Median | 17.6 | Median | 3D : 3.7 | 35.3 | 4 | CTC V3 | |
3D : 60 | 88 (2-y) | (AT) | 15 (1-43) | IMRT : 20.8 | |||||
IMRT : 23 | 65.8 (2-y) | (P=0.088) |